The Chinese herbal formula Shen Huang granule reduces the chances of dying from COVID19

This was an open-label, multicenter, randomized, controlled clinical trial. At 4 medical centers, a total of 111 severe/critical patients were randomly assigned to receive Shenhuang Granule (SHG group) twice a day for 14 days, in addition to standard care, or to receive standard care alone (Control group). The maximal follow up time was 75 days. The clinical endpoint was clinical improvement and mortality.


54 patients were assigned to the control group and 57 to the SHG group. The overall mortality was 75.9% (41/54) in the control group, and 38.6% (22/57) in the SHG group (p < 0.01 vs. control). The post hoc analysis showed that in the severe category, the mortality of the control group vs. the SHG group was 58.8% (10/17) vs. 5.3% (1/19) (p < 0.01); while in the critical category, it was 83.8% (31/37) vs. 55.3% (21/38) (p < 0.05). In the severe category, the mortality of patients who eventually received an invasive ventilator in the control vs. the SHG group was 58.8% (10/17) vs. 0 (0/19) (p < 0.01). Administration of SHG was associated with increased lymphocytes and decreased adverse events.


Shenhuang Granule is a promising integrative therapy for severe and critical COVID-19.


Acupuncture Times Logo

Hi there!

Sign up to receive the latest research in acupuncture, cupping, moxibustion, Chinese herbal medicine and more, once a week.

About Attilio

Doctor of Chinese medicine, acupuncture expert and author of My Fertility Guide and My Pregnancy Guide.

Check Also

Pub Med

The Chinese herbal formula Sun Jun Zi Tang aids in recovery from lung cancer surgery

Background: Postoperative non-small cell lung cancer (NSCLC) patients frequently encounter a deteriorated quality of life (QOL), …